Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein …

S Mandel, T Amit, O Bar-Am, MBH Youdim - Progress in neurobiology, 2007 - Elsevier
Considering the multi-etiological character of Alzheimer's disease (AD), the current pharmacological
approaches using drugs oriented towards a single molecular target possess limited …

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

O Weinreb, T Amit, O Bar-Am, MBH Youdim - Progress in neurobiology, 2010 - Elsevier
… The last two compounds are selective irreversible inhibitors of MAO type A, having N-cyclopropylamine
structure in which O–CH2–CH2-moieties occupy the distance between the …

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

…, O Bar Am, M Yogev‐Falach, O Weinreb… - Journal of …, 2005 - Wiley Online Library
Mitochondria are involved directly in cell survival and death. The assumption has been
made that drugs that protect mitochondrial viability and prevent apoptotic cascade‐induced …

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative …

H Zheng, LM Weiner, O Bar-Am, S Epsztejn… - Bioorganic & medicinal …, 2005 - Elsevier
… It is known that the formation of radical dot OH by photolysis of H 2 O 2 is iron-independent
but catalyzed by light. Compound 9 (HLA20) remarkably decrease the intensity of the DMPO- …

… iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and …

H Zheng, S Gal, LM Weiner, O BarAm… - Journal of …, 2005 - Wiley Online Library
… reduce the DMPO-OH signal generated by the photolysis of H 2 O 2 . This suggests that …
radical, because the photolysis of H 2 O 2 generates OH • independently from metal ions. The …

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

O Weinreb, T Amit, O Bar-Am… - Current drug …, 2012 - ingentaconnect.com
Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] is a dual
acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B …

… targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1

Y Avramovich‐Tirosh, T Amit, O BarAm… - Journal of …, 2007 - Wiley Online Library
Novel therapeutic approaches for the treatment of neurodegenerative disorders comprise
drug candidates designed specifically to act on multiple CNS targets. We have synthesized a …

Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

O BarAm, O Weinreb, T Amit… - The FASEB journal, 2005 - Wiley Online Library
The anti‐Parkinson drug, rasagiline (N‐propargyl‐(1R)‐aminoindan) promotes neuronal
survival, via neuroprotective activity related to its propargyl moiety (propargylamine). We have …

Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

O Weinreb, O BarAm, T Amit… - The FASEB …, 2004 - Wiley Online Library
This study provides new insights into neuroprotection involving interaction of protein kinase
C (PKC) pathway with Bcl‐2 family proteins. Using a model of serum deprivation, we …

[HTML][HTML] Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs

O Weinreb, S Mandel, O Bar-Am, M Yogev-Falach… - …, 2009 - Elsevier
… to significantly protect rat PC12 cells against H 2 O 2 insult. Similarly, ladostgil was found
to comprise a significant neuroprotective effect against H 2 O 2 -induced damage in SH-SY5Y …